


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A substituted methylene amide of Formula (I) :

as well as its geometrical isomers, its optically active forms as enantiomers,



diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof,  
wherein

(I)

R<sup>1</sup> is CH<sub>2</sub>-CH<sub>2</sub>-phenyl, CH<sub>2</sub>-CH<sub>2</sub>-naphthyl, CH<sub>2</sub>-phenyl, or CH<sub>2</sub>-naphthyl;

R<sup>2a</sup> and R<sup>2b</sup> are each independently are H or (C<sub>1</sub>-C<sub>12</sub>)alkyl;

Cy is a phenyl substituted by (1), (2) or (3):

(1) an oxadiazole group;

(2) 1 or 2 moieties selected from the group consisting of -NH-CO-R<sup>3</sup>, -SO<sub>2</sub>-NR<sup>3</sup>R<sup>3'</sup>

and -CO-NR<sup>3</sup>R<sup>3'</sup> wherein R<sup>3</sup> and R<sup>3'</sup> are independently selected from H and (C<sub>1</sub>-C<sub>15</sub>)alkyl; or

(3) B-R<sup>4</sup> wherein B is an ethynyl group and R<sup>4</sup> is a (C<sub>1</sub>-C<sub>12</sub>)alkyl phenyl; ~~wherein~~

(II)

~~when~~ R<sup>2a</sup> and R<sup>2b</sup> are each H, R<sup>1</sup> is -CH<sub>2</sub>-A with A being phenyl optionally substituted by cyano, halogen, methoxy, hydroxyl, phenoxy, -NO<sub>2</sub>, or trifluoromethyl, and Cy is phenyl or biphenyl substituted by -SO<sub>2</sub>R<sup>3</sup>, or -CO-NR<sup>3</sup>R<sup>3'</sup> where R<sup>3'</sup> is H and R<sup>3</sup> is (C<sub>7</sub>-C<sub>12</sub>) alkyl or (C<sub>7</sub>-C<sub>15</sub>)alkyl; or

(III)

~~when~~ R<sup>2a</sup> and R<sup>2b</sup> are each H, R<sup>1</sup> is selected from the group consisting of phenyl, benzyl, phenethyl, or 1-methylbenzyl which may be substituted by (C<sub>1</sub>-C<sub>6</sub>)alkyl or

cycloalkyl, and Cy is phenyl or biphenyl substituted by  $-\text{SO}_2\text{R}^3$ , or  $-\text{CO}-\text{NR}^3\text{R}^{3'}$  where  $\text{R}^3$  is  $(\text{C}_7-\text{C}_{15})\text{alkyl}$ .

Claims 2-4 (Cancelled).

Claim 5 (Previously Presented): The substituted methylene amide according to claim 1, wherein  $\text{R}^{3'}$  is H and  $\text{R}^3$  is selected from the group consisting of diphenyl-ethyl, dodecyl, octyl, 4-pentyl-benzyl, 4-phenoxy-phenethyl, ethyl-thiophen-2-yl, pentadecyl, tridecyl, hexyloxy-phenyl or (2-ethyl)-hexyl.


Claims 6-11 (Cancelled).

Claim 12 (Previously Presented): The substituted methylene amide according to claim 1 wherein:

$\text{R}^{2a}$  and  $\text{R}^{2b}$  are each H.

Claim 13 (Cancelled).

Claim 14 (Previously Presented): A substituted methylene amide of Formula (I'):  
wherein



R<sup>1</sup> is which may be substituted by (C<sub>1</sub>-C<sub>6</sub>)alkyl group or a cycloalkyl group;

Cy is a phenyl substituted with a moiety selected from the group consisting of -NH-CO-R<sup>3</sup>, -CO-NH-R<sup>3</sup>.

15-26 (Canceled).

Claim 27 (Previously Presented): A pharmaceutical composition comprising at least one substituted methylene amide according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 28 (Previously Presented): The pharmaceutical composition according to claim 27 further comprising at least one supplementary drug.

Claim 29-41 (Cancelled)

Claim 42 (Previously Presented) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 5 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 43 (Previously Presented) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 12 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 44 (Previously Presented) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 14 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 45 (Previously Presented) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 15 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 46 (Previously Presented) { {4-[(4-hexylphenyl)ethynyl]benzyl}{4-(trifluoromethyl)benzyl}amino}-(oxo)acetic acid.

Claim 47 (Previously Presented) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 46 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 48 (Previously Presented) The substituted methylene amide of Formula (I) as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof according to Claim 1,  $R^{2a}$  and  $R^{2b}$  are each H,  $R^1$  is  $-CH_2-A$  with A being phenyl optionally substituted by cyano, halogen, methoxy, hydroxyl, phenoxy,  $-NO_2$ , or trifluoromethyl, and Cy is phenyl or biphenyl substituted by  $-SO_2R^3$ , or  $-CO-NR^3R^{3'}$  where  $R^{3'}$  is H and  $R^3$  is  $(C_7-C_{12})$  alkyl or  $(C_7-C_{15})$ alkyl.

Claim 49 (Previously Presented) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 48 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 50 (Previously Presented) The substituted methylene amide of Formula (I) as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts-thereof according to Claim 1, wherein  $R^{2a}$  and  $R^{2b}$  are each H,  $R^1$  is selected from the group consisting of phenyl, benzyl, phenethyl, or 1-methylbenzyl which may be substituted by  $(C_1-C_6)$ alkyl or cycloalkyl, and Cy is phenyl or biphenyl substituted by  $-SO_2R^3$ , or  $-CO-NR^3R^{3'}$  where  $R^3$  is  $(C_7-C_{15})$ alkyl.

Claim 51 (Previously Presented) A pharmaceutical composition comprising at least one substituted methylene amide according to claim 50 and a pharmaceutically acceptable carrier, diluent or excipient thereof.